NeuroBloc

botulinum toxin type B

  • Email
  • Help

About

An overview of NeuroBloc and why it is authorised in the EU

NeuroBloc is a medicine used to treat cervical dystonia in adults. Cervical dystonia, which is also known as torticollis, is a disorder when the neck muscles contract, causing abnormal movement and twisting of the neck and unusual positioning of the head.

NeuroBloc contains the active substance botulinum toxin type B.

How is NeuroBloc used?

NeuroBloc is available as a solution for injection (5,000 units [U] per millilitre) and it can only be obtained with a prescription. It is only used in hospitals, by a doctor who has experience in the treatment of cervical dystonia and in the use of botulinum toxins. NeuroBloc treatment starts with 10,000 U, divided into equal doses and injected directly into the two to four muscles in the neck and shoulders that are most affected. The dose and number of injections depend on the patient’s response.

For more information about using NeuroBloc, see the package leaflet or contact your doctor or pharmacist.

How does NeuroBloc work?

The active substance in NeuroBloc, botulinum toxin type B, is a well-known toxic substance produced by the bacterium Clostridium botulinum. The toxin is the cause of a type of food poisoning called botulism, where patients suffer from muscle weakness and paralysis. The toxin reduces the release of acetylcholine from the nerve endings. Acetylcholine is needed to transfer electrical impulses from the nerves to the muscles in order for the muscles to contract.

In NeuroBloc, the toxin is used as a muscle relaxant. When injected directly into a muscle it reduces the release of acetylcholine and muscle contraction in the affected neck or shoulder muscles, thereby relieving the patient’s symptoms. The effect of an injection of NeuroBloc gradually wears off over time.

What benefits of Neurobloc have been shown in studies?

NeuroBloc was more effective than placebo (a dummy treatment) at improving symptoms of cervical dystonia in four studies involving a total of 392 adults.

Three of the studies included patients who had stopped responding to type A botulinum toxin (another type of botulinum toxin that may also be used to treat cervical dystonia), and the fourth only included patients who did respond to type A toxin. Effectiveness was measured by looking at the change in symptoms (severity, pain and disability) after four weeks, measured using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS).

The medicine improved the TWSTRS score of the non‑responders to type A botulinum toxin as well as the score of the responders. Most patients who had a response to NeuroBloc by the fourth week had returned to their original condition 12 to 16 weeks after the injection.

What are the risks associated with NeuroBloc?

The most common side effects with NeuroBloc (which may affect more than 1 in 10 people) are dry mouth, headache (in patients new to treatment with botulinum toxins), dysphagia (difficulty swallowing) and pain at the site of the injection. For the full list of side effects reported with NeuroBloc, see the package leaflet.

NeuroBloc must not be used in patients with other neuromuscular (nerve and muscle) disorders. For the full list of restrictions, see the package leaflet.

Why is NeuroBloc authorised in the EU?

The European Medicines Agency decided that NeuroBloc’s benefits are greater than its risks and it can be authorised for use in the EU.

What measures are being taken to ensure the safe and effective use of NeuroBloc?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of NeuroBloc have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of NeuroBloc are continuously monitored. Side effects reported with NeuroBloc are carefully evaluated and any necessary action taken to protect patients.

Other information about NeuroBloc

NeuroBloc received a marketing authorisation valid throughout the EU on 22 January 2001.

Name Language First published Last updated
NeuroBloc : EPAR - Summary for the public BG = bălgarski 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public ES = español 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public CS = čeština 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public DA = dansk 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public DE = Deutsch 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public ET = eesti keel 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public EL = elliniká 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public EN = English 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public FR = français 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public IT = italiano 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public LV = latviešu valoda 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public LT = lietuvių kalba 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public HU = magyar 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public MT = Malti 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public NL = Nederlands 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public PL = polski 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public PT = português 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public RO = română 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public SK = slovenčina 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public SL = slovenščina 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public FI = suomi 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public SV = svenska 2008-01-31 2018-07-13
NeuroBloc : EPAR - Summary for the public HR = Hrvatski 2008-01-31 2018-07-13

This EPAR was last updated on 13/07/2018 .

Authorisation details

Product details

Product details for NeuroBloc
NameNeuroBloc
Agency product numberEMEA/H/C/000301
Active substance

botulinum toxin type B

International non-proprietary name (INN) or common name

botulinum toxin type B

Therapeutic area Torticollis
Anatomical therapeutic chemical (ATC) code M03AX01

Publication details

Publication details for NeuroBloc
Marketing-authorisation holder

Eisai Ltd.

Revision29
Date of issue of marketing authorisation valid throughout the European Union22/01/2001

Contact address:

Eisai Ltd.
European Knowledge Centre
Mosquito Way
Hatfield
Hertfordshire
AL10 9SN
United Kingdom

Product information

Product information

23/04/2018  NeuroBloc -EMEA/H/C/000301 -PSUSA/00000428/201706

Name Language First published Last updated
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02
NeuroBloc : EPAR - Product Information HR = Hrvatski 2009-08-25 2018-05-02

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
NeuroBloc : EPAR - All Authorised presentations HR = Hrvatski 2008-06-01  
NeuroBloc : EPAR - All Authorised presentations HR = Hrvatski 2008-06-01  
NeuroBloc : EPAR - All Authorised presentations HR = Hrvatski 2008-06-01  
NeuroBloc : EPAR - All Authorised presentations HR = Hrvatski 2008-06-01  
NeuroBloc : EPAR - All Authorised presentations HR = Hrvatski 2008-06-01  
NeuroBloc : EPAR - All Authorised presentations HR = Hrvatski 2008-06-01  
NeuroBloc : EPAR - All Authorised presentations HR = Hrvatski 2008-06-01  
NeuroBloc : EPAR - All Authorised presentations HR = Hrvatski 2008-06-01  
NeuroBloc : EPAR - All Authorised presentations HR = Hrvatski 2008-06-01  
NeuroBloc : EPAR - All Authorised presentations HR = Hrvatski 2008-06-01  
NeuroBloc : EPAR - All Authorised presentations HR = Hrvatski 2008-06-01  

Pharmacotherapeutic group

Muscle relaxants

Therapeutic indication

NeuroBloc is indicated for the treatment of cervical dystonia (torticollis).

See section 5.1 for data on efficacy in patients responsive / resistant to botulinum toxin type A.

Assessment History

Changes since initial authorisation of medicine

Initial marketing-authorisation documents

Name Language First published Last updated
NeuroBloc : EPAR - Procedural steps taken before authorisation HR = Hrvatski 2008-06-01  
NeuroBloc : EPAR - Scientific Discussion HR = Hrvatski 2008-06-01  

Authorised

This medicine is approved for use in the European Union